Sunday - December 22, 2024
GSK: ViiV Healthcare Announces CHMP Positive Opinion for Vocabria + Rekambys, the First and Only Complete Long-Acting HIV Treatment, for Adolescents in Europe
December 17, 2024
LONDON, England, Dec. 17 (TNSres) -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Dec. 16, 2024:

* * *

- Vocabria + Rekambys (cabotegravir + rilpivirine) is the first and only complete long-acting regimen for the treatment of HIV, reducing dosing days from 365 to 6 per year

- At just 65% globally, treatment coverage for 10 - 19-year-olds living with HIV is lagging behind UNAIDS's target, demonstrating nee . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation
Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products